Webinar Date/Time: Tue, Nov 28, 2023 11:00 AM EST
Join this webinar to learn how to ensure gain of time and success of lentiviral-based therapies from process development up to market approval.
Plasmid DNA is a critical raw material that is required for the manufacturing of virus-based gene therapy and gene-modified cell therapies. The current challenges with the supply of plasmid DNA varies depending on its end use, but usually production capacity, costs of manufacturing and meeting regulatory compliance are the common denominators. Join this webinar to hear from Philippe Ledent, Chief Scientific Director at Xpress Biologics, now part of Sartorius and Rakel Lopez de Maturana, Qualified Person & Regulatory Affairs Director at VIVEbiotech discuss how to ensure gain of time and success of lentiviral-based therapies from process development up to market approval.
Key Learning Objectives:
Who Should Attend:
Rakel Lopez de Maturana
Qualified Person & Regulatory
Rakel holds a doctoral degree in pharmacy from the University of Leeds. She started off her research activity in pharmacology, studying the structure and function of G protein-coupled receptors (GPCRs) at Leeds & MRC Edinburgh. She investigated the mechanisms of pathogenicity in neurodegenerative diseases for more than 10 years, first in Alzheimer’s disease (CIMA University of Navarra) and later in Parkinson’s disease (Inbiomed Foundation and VIVEbiotech, San Sebastian-Donostia).
Rakel is the Qualified Person and Regulatory Affairs Director at VIVEbiotech.
Chief Scientific Director
Philippe graduated in 1995 with a Ph.D. in Biochemistry from the University of Liège in Belgium. He studied at the Centre for Protein Engineering the resistance mechanisms developed by bacteria against β-lactam antibiotics. He acquired extensive expertise in molecular biology, fermentation, protein purification and characterization.
After an additional year at the University of Liège where he studied thermodynamical and kinetic properties of enzymes produced by extremophile microorganisms, Philippe began to work in 1996 as Scientist at the Unit of Bioengineering at University of Louvain-la-Neuve in the field of environmental biotechnology.
In 1999, he became R&D Manager at Realco, a SME based in Louvain-la-Neuve, a company active in the development of enzyme and microorganism-based products for household and industry applications, including wastewater treatment and farming applications.